MedTrace Logo

A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.

NCT02401373 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2015-07-16

No results posted yet for this study

Summary

This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between 18-60 years in China.

Conditions

  • Ebola Virus Disease

Interventions

BIOLOGICAL

Ad5-EBOV

intramuscular injection

Sponsors & Collaborators

  • Beijing Institute of Bioengineering, Academy of Military Medical Sciences

    collaborator UNKNOWN

  • Tianjin Cansino Biotechnology Inc

    collaborator INDUSTRY

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Lanjuan Li · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02401373 on ClinicalTrials.gov